Therapeutic Effect of Sodium Iodide Symporter Gene Therapy Combined With External Beam Radiotherapy and Targeted Drugs That Inhibit DNA Repair |
| |
Authors: | Mohan Hingorani Christine L White Shane Zaidi Hardev S Pandha Alan A Melcher Shreerang A Bhide Christopher M Nutting Konstantinos N Syrigos Richard G Vile Georges Vassaux Kevin J Harrington |
| |
Institution: | 1Targeted Therapy Team, The Institute of Cancer Research, London, UK;2Postgraduate Medical School, University of Surrey, Guildford, UK;3St James''s University Hospital, Leeds, UK;4Head and Neck Unit, Royal Marsden Hospital, London, UK;5Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota, USA;6Inserm U948, Nantes, France |
| |
Abstract: | Adenoviral (AdV) transfer of sodium iodide symporter (NIS) gene has translational potential, but relatively low levels of transduction and subsequent radioisotope uptake limit the efficacy of the approach. In previous studies, we showed that combining NIS gene delivery with external beam radiotherapy (EBRT) and DNA damage repair inhibitors increased viral gene expression and radioiodide uptake. Here, we report the therapeutic efficacy of this strategy. An adenovirus expressing NIS from a telomerase promoter (Ad-hTR-NIS) was cytotoxic combined with relatively high-dose (50 µCi) 131I therapy and enhanced the efficacy of EBRT combined with low-dose (10 and 25 µCi) 131I therapy in colorectal and head and neck cancer cells. Combining this approach with ataxia-telangiectasia mutated (ATM) or DNA-dependent protein kinase (DNA-PK) inhibition caused maintenance of double-stranded DNA breaks (DSBs) at 24 hours and increased cytotoxicity on clonogenic assay. When the triplet of NIS-mediated 131I therapy, EBRT, and DNA-PKi was used in vivo, 90% of mice were tumor-free at 5 weeks. Acute radiation toxicity in the EBRT field was not exacerbated. In contrast, DNA-PKi did not enhance the therapeutic efficacy of EBRT plus adenovirus-mediated HSVtk/ganciclovir (GCV). Therefore, combining NIS gene therapy and EBRT represents an ideal strategy to exploit the therapeutic benefits of novel radiosensitizers. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|